Holzbach R, Martens M, Kalke J, Raschke P
LWL-Kliniken Warstein und Lippstadt, Franz-Hegemann-Str. 23, 59581, Warstein, Deutschland.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Apr;53(4):319-25. doi: 10.1007/s00103-010-1029-8.
The administration of benzodiazepines in suicidal, anxious, or agitated patients with depression is common international practice. Nevertheless, the prescription of BZDs is recommended to be limited to a period of a few weeks. There are several epidemiological studies about the situation in Germany, but many questions are still unanswered. The BfArM sought a new method to track prescription of medications with the risk to induce dependency. The present article describes the methodology and the early results of the pilot study. As a new approach, data from a processing center for pharmacies were used; patient-years, a risk scale with six steps, and diazepam-equivalence dose instead of defined daily dose were used for the analysis. About 35% of prescriptions were long-term treatment. Even if several physicians prescribe the medication, the main physician prescribing the medication can identify the risk level of the patient in 80-90% of cases.
在患有抑郁症的自杀倾向、焦虑或烦躁不安的患者中使用苯二氮䓬类药物是国际通行做法。然而,苯二氮䓬类药物的处方建议限制在几周时间内。德国有多项关于这一情况的流行病学研究,但许多问题仍未得到解答。德国药品和医疗器械管理局寻求一种新方法来追踪有导致药物依赖风险的药物处方情况。本文描述了该试点研究的方法和初步结果。作为一种新方法,使用了来自药房处理中心的数据;分析采用了患者年数、一个六级风险量表以及地西泮等效剂量而非限定日剂量。约35%的处方属于长期治疗。即使有多位医生开具药物,开具药物的主诊医生在80%至90%的病例中能够识别患者的风险水平。